{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:01:26Z","timestamp":1780124486494,"version":"3.54.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03517-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:21:33Z","timestamp":1775024493000},"page":"2611-2630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase\u00a02a Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03695185","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Seenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Blink","family":"Polakow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"al Mahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"1","key":"3517_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6(1):74.","journal-title":"Nat Rev Dis Prim"},{"key":"3517_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756\u201370.","journal-title":"Lancet"},{"key":"3517_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105040","volume":"159","author":"P Giuffrida","year":"2020","unstructured":"Giuffrida P, Di Sabatino A. Targeting T\u00a0cells in inflammatory bowel disease. Pharmacol Res. 2020;159:105040.","journal-title":"Pharmacol Res"},{"issue":"18","key":"3517_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713\u201325.","journal-title":"N Engl J Med"},{"issue":"10","key":"3517_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/ecco-jcc\/jjx077","volume":"11","author":"J Burisch","year":"2017","unstructured":"Burisch J, Vegh Z, Katsanos KH, et al. Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort\u2014an ECCO-EpiCom study. J Crohns Colitis. 2017;11(10):1213\u201322.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3517_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","volume":"10","author":"D Farrell","year":"2016","unstructured":"Farrell D, McCarthy G, Savage E. Self-reported symptom burden in individuals with inflammatory bowel disease. J Crohns Colitis. 2016;10(3):315\u201322.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"3517_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","volume":"8","author":"S L\u00f6nnfors","year":"2014","unstructured":"L\u00f6nnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life\u2014discovering the true impact. J Crohns Colitis. 2014;8(10):1281\u20136.","journal-title":"J Crohns Colitis"},{"key":"3517_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3517_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"10292","key":"3517_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase\u00a02b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372\u201384.","journal-title":"Lancet"},{"issue":"23","key":"3517_CR11","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"257\u201365","key":"3517_CR12","first-page":"1","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Assche G, Reinisch W. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(257\u201365):1\u20133.","journal-title":"Gastroenterology"},{"issue":"1","key":"3517_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85\u201395.","journal-title":"Gastroenterology"},{"issue":"1","key":"3517_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96-109.e1.","journal-title":"Gastroenterology"},{"issue":"8","key":"3517_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"key":"3517_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"3517_CR17","unstructured":"Louis E, Schreiber S, Panaccione R, et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2821291. Accessed 2024 Jul 25."},{"issue":"10472","key":"3517_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase\u00a03 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405(10472):33\u201349.","journal-title":"Lancet"},{"key":"3517_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391.","journal-title":"N Engl J Med"},{"issue":"10383","key":"3517_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase\u00a03 studies. Lancet. 2023;401(10383):1159\u201371.","journal-title":"Lancet"},{"key":"3517_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"issue":"10341","key":"3517_CR22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase\u00a03, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328.","journal-title":"Lancet"},{"issue":"10340","key":"3517_CR23","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase\u00a03 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330.","journal-title":"Lancet"},{"issue":"26","key":"3517_CR24","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"7","key":"3517_CR25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/gut.2003.026278","volume":"53","author":"S Danese","year":"2004","unstructured":"Danese S. The CD40\/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004;53(7):1035\u201343.","journal-title":"Gut"},{"key":"3517_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","volume":"141","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92\u2013103.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3517_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12860-019-0213-4","volume":"20","author":"MA Argiriadi","year":"2019","unstructured":"Argiriadi MA, Benatuil L, Dubrovska I, et al. CD40\/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019;20(1):29.","journal-title":"BMC Mol Cell Biol"},{"key":"3517_CR28","series-title":"Advances in experimental medicine and biology","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","volume-title":"Therapeutic targets of the TNF superfamily","author":"CL Law","year":"2009","unstructured":"Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. In: Grewal IS, editor. Therapeutic targets of the TNF superfamily, vol. 647. Advances in experimental medicine and biology. New York: Springer; 2009. p. 8\u201336. https:\/\/doi.org\/10.1007\/978-0-387-89520-8_2."},{"issue":"9","key":"3517_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/j.1600-6143.2004.00523.x","volume":"4","author":"T Kawai","year":"2004","unstructured":"Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant. 2004;4(9):1391\u20138.","journal-title":"Am J Transplant"},{"issue":"3","key":"3517_CR30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","volume":"185","author":"L Robles-Carrillo","year":"2010","unstructured":"Robles-Carrillo L, Meyer T, Hatfield M, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010;185(3):1577\u201383.","journal-title":"J Immunol"},{"issue":"1","key":"3517_CR31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4049\/jimmunol.174.1.542","volume":"174","author":"AB Adams","year":"2005","unstructured":"Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005;174(1):542\u201350.","journal-title":"J Immunol"},{"issue":"5","key":"3517_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-3083.2007.01927.x","volume":"65","author":"TB Hunter","year":"2007","unstructured":"Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell\/lymph node cell model. Scand J Immunol. 2007;65(5):479\u201386.","journal-title":"Scand J Immunol"},{"issue":"21","key":"3517_CR33","doi-asserted-by":"publisher","first-page":"12869","DOI":"10.3390\/ijms232112869","volume":"23","author":"I Lang","year":"2022","unstructured":"Lang I, Zaitseva O, Wajant H. Fc\u03b3Rs and their relevance for the activity of anti-CD40 antibodies. Int J Mol Sci. 2022;23(21):12869.","journal-title":"Int J Mol Sci"},{"issue":"S1","key":"3517_CR34","first-page":"PII-004","volume":"113","author":"S Bhatnagar","year":"2023","unstructured":"Bhatnagar S, Hao S, Hew K, et al. Phase\u00a01 development of ravagalimab, an anti CD40 monoclonal antibody, to support dose selection for phase\u00a02. Clin Pharmacol Ther. 2023;113(S1):PII-004.","journal-title":"Clin Pharmacol Ther"},{"issue":"S8","key":"3517_CR35","first-page":"P1120","volume":"7","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Clarke S, McRae B, et al. Translational studies in nonhuman primates and human volunteers support the phase\u00a02 program for ravagalimab in moderately to severely active ulcerative colitis. United Eur Gastroenterol J. 2019;7(S8):P1120.","journal-title":"United Eur Gastroenterol J"},{"key":"3517_CR36","unstructured":"Evaluation of sex differences in clinical investigations. Office of the Commissioner, Office of the Chief Medical Officer, Office of Clinical Policy; 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-sex-differences-clinical-investigations. Accessed 2025 Nov 13."},{"issue":"2","key":"3517_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","volume":"37","author":"GE Hoffman","year":"2021","unstructured":"Hoffman GE, Roussos P. Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics. 2021;37(2):192\u2013201.","journal-title":"Bioinformatics"},{"issue":"10","key":"3517_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/gut.52.10.1448","volume":"52","author":"CM Gelbmann","year":"2003","unstructured":"Gelbmann CM, Leeb SN, Vogl D, et al. Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts. Gut. 2003;52(10):1448\u201356.","journal-title":"Gut"},{"issue":"30","key":"3517_CR39","doi-asserted-by":"publisher","first-page":"eaba2619","DOI":"10.1126\/sciadv.aba2619","volume":"6","author":"K Menden","year":"2020","unstructured":"Menden K, Marouf M, Oller S, et al. Deep learning-based cell composition analysis from tissue expression profiles. Sci Adv. 2020;6(30):eaba2619.","journal-title":"Sci Adv"},{"issue":"8","key":"3517_CR40","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3390\/ijms23084115","volume":"23","author":"HD Ots","year":"2022","unstructured":"Ots HD, Tracz JA, Vinokuroff KE, Musto AE. CD40\u2013CD40L in neurological disease. Int J Mol Sci. 2022;23(8):4115.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3517_CR41","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139-2149.e14.","journal-title":"Gastroenterology"},{"key":"3517_CR42","doi-asserted-by":"crossref","unstructured":"Ghusn W. Disparities in the burden of gastrointestinal diseases: a comprehensive analysis of data from randomized clinical trials from 2000\u20132023. Ann Gastroenterol. 2025. http:\/\/www.annalsgastro.gr\/files\/journals\/1\/earlyview\/2025\/ev-08-2025-14-AG_8024-0997.pdf. Accessed 2025 Nov 13.","DOI":"10.20524\/aog.2025.0997"},{"issue":"50","key":"3517_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046562","volume":"104","author":"A Atay","year":"2025","unstructured":"Atay A, Ergul M, Ozturk O, et al. Male predominance in inflammatory bowel disease despite similar disease activity: a large retrospective cohort study. Medicine (Baltimore). 2025;104(50):e46562.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3517_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152\u201372.","journal-title":"Immunol Rev"},{"issue":"3","key":"3517_CR45","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/clinem\/dgz013","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ, Stan MN, Frommer L, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism\u2014a proof-of-concept trial. J Clin Endocrinol Metab. 2020;105(3):696\u2013704.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3517_CR46","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","volume":"2","author":"BA Fisher","year":"2020","unstructured":"Fisher BA, Szanto A, Ng WF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2020;2(3):e142\u201352.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3517_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/ajt.15661","volume":"20","author":"P Espi\u00e9","year":"2020","unstructured":"Espi\u00e9 P, He Y, Koo P, et al. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. Am J Transplant. 2020;20(2):463\u201373.","journal-title":"Am J Transplant"},{"issue":"2","key":"3517_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3517_CR49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2020.04.013","volume":"37","author":"X Yu","year":"2020","unstructured":"Yu X, Chan HTC, Fisher H, et al. Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity. Cancer Cell. 2020;37(6):850-866.e7.","journal-title":"Cancer Cell"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03517-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:18Z","timestamp":1780120998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03517-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3517"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03517-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laurent Peyrin-Biroulet has received consulting\/advisory board fees, speaker\u2019s fees, and\/or research support from AbbVie, Abivax, Adacyte, Alfasigma, Alimentiv, Amgen, Apini, Applied Molecular Transport, Arena, Banook, Biogen BMS, Celltrion, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Iterative Health, Janssen, Lilly, LifeMine, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign, Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Par'Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, Ventyx.\u00a0John Paul Seenan has received consulting\/advisory board fees from AbbVie, Falk, and Galapagos; and speaker\u2019s fees from AbbVie, Fresenius-Kabi, Janssen-Cilag, Pharmacosmos, Takeda, and Tillotts. Alessandro Armuzzi has received consulting\/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Nestl\u00e9, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; speaker\u2019s fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; and research support from MSD, Takeda, Pfizer, and Biogen. Dr. Armuzzi is currently affiliated with the IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy and the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Stefan Schreiber has received speaker\/consultancy fees from AbbVie, Advanced Molecular Transport, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Falk, Ferring Pharmaceuticals, Galapagos\/Gilead, Genentech\/Roche, Janssen, Merck\/MSD, Pfizer, Prometheus, and Takeda. Andreas Lazar, Ann Eldred, Thao Doan, Sarah Blink Polakow, Naim al Mahi, Meng Liu, and Sumit Bhatnagar are employees of AbbVie Inc. and may hold AbbVie stock and\/or stock options. Ahmed Nader was an employee of AbbVie Inc. at the time of the study and may hold AbbVie stock and\/or stock options. Dr. Nader is a current employee of GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trial protocol, amendments, and trial patient informed consent were reviewed and approved by a national, regional, or independent ethics committee or institutional review board (full list available in Supplementary Materials). The study was conducted and reported in accordance with the protocol and in accordance with the International Conference on Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Patients\u2019 informed consent was obtained and documented before trial participation. Consent was obtained for participation in the research study and for the collection, use, and sharing of de-identified personal health information and biological samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}